Skip to content

Predictive relevance of genetic polymorphisms in the glycogen-synthase-kinase-3beta (GSK3B) mediated intracellular signal transduction for the efficacy of lithium augmentation of antidepressants in the treatment-resistant major depression

Predictive relevance of genetic polymorphisms in the glycogen-synthase-kinase-3beta (GSK3B) mediated intracellular signal transduction for the efficacy of lithium augmentation of antidepressants in the treatment-resistant major depression - ALIA

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00026205
Enrollment
500
Registered
2021-09-14
Start date
2009-09-29
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F33

Interventions

Group 1: After four weeks of adequately dosed antidepressant treatment with at least one antidepressant (at least 10mg escitalopram equivalent/die p.o., tablets) without sufficient treatment success (

Sponsors

Charité - Universitätsmedzin Berlin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: -unipolar major depression -indication for antidepressant pharmacotherapy -HAMD-17 = 12 -Inadequate response to antidepressant monotherapy and indication for lithium augmentation. -Minimum age: 18 years -physician-confirmed capacity to consent -written informed consent -No participation in an AMG study (1 month prior) and during study participation.

Exclusion criteria

Exclusion criteria: -psychotic symptoms, current -Contraindication to lithium therapy (e.g. severe renal insufficiency, pathological TSH or relevant ECG changes) - for a list of contraindications, see the technical information in the appendix. -laboratory values and/or ECG findings that speak against taking lithium -depressive syndrome due to a non-psychiatric or in the context of a further axis I diagnosis -diagnosis of dementia or organic brain disease -Diagnosis of substance dependence and use of the substance in the last 6 months (except caffeine and nicotine) -Diagnosis of an antisocial personality disorder

Design outcomes

Primary

MeasureTime frame
Response and remission assessment using HAMD (Hamilton Depression Rating Scale) after at least four weeks of therapy with lithium carbonate in patients with treatment-resistant unipolar depression

Secondary

MeasureTime frame
1) Tolerability and safety (Adverse Event Report, ECG, laboratory tests, self-rating questionnaires), assessment before and during lithium therapy. 2) pharmacogenetic studies 3) peripheral cytokine concentration in serum before and during lithium therapy 4) Expolorative investigation of further clinical data, e.g. childhood trauma and quality of life

Countries

Germany

Contacts

Public ContactMazda Adli

Charité - Universitätsmedzin Berlin

mazda.adil@charite.de030450517296

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jul 19, 2026